Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Papillon-Lefevre syndrome Indication Strategy Report 2026: CTSC, Trials and Deals
3 August 2026
2026 Papillon-Lefevre syndrome indication strategy covering epidemiology, CTSC biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Pachyonychia congenita Indication Strategy Report 2026: KRT6A, Trials and Deals
3 August 2026
2026 Pachyonychia congenita indication strategy covering epidemiology, KRT6A biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Olmsted syndrome Indication Strategy Report 2026: TRPV3, Trials and Deals
3 August 2026
2026 Olmsted syndrome indication strategy covering epidemiology, TRPV3 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Palmoplantar keratoderma Indication Strategy Report 2026: KRT9, Trials and Deals
3 August 2026
2026 Palmoplantar keratoderma indication strategy covering epidemiology, KRT9 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Keratoderma blennorrhagicum Indication Strategy Report 2026: IL-17, Trials and Deals
3 August 2026
2026 Keratoderma blennorrhagicum indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Epidermolytic ichthyosis Indication Strategy Report 2026: KRT10, Trials and Deals
3 August 2026
2026 Epidermolytic ichthyosis indication strategy covering epidemiology, KRT10 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Congenital ichthyosiform erythroderma Indication Strategy Report 2026: ALOX12B, Trials and Deals
3 August 2026
2026 Congenital ichthyosiform erythroderma indication strategy covering epidemiology, ALOX12B biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Peeling skin syndrome Indication Strategy Report 2026: CDSN, Trials and Deals
3 August 2026
2026 Peeling skin syndrome indication strategy covering epidemiology, CDSN biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Recessive dystrophic epidermolysis bullosa Indication Strategy Report 2026: COL7A1, Trials and Deals
3 August 2026
2026 Recessive dystrophic epidermolysis bullosa indication strategy covering epidemiology, COL7A1 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Harlequin ichthyosis Indication Strategy Report 2026: ABCA12, Trials and Deals
3 August 2026
2026 Harlequin ichthyosis indication strategy covering epidemiology, ABCA12 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Porokeratosis Indication Strategy Report 2026: MVK, Trials and Deals
3 August 2026
2026 Porokeratosis indication strategy covering epidemiology, MVK biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Transient acantholytic dermatosis Indication Strategy Report 2026: ATP2A2, Trials and Deals
3 August 2026
2026 Transient acantholytic dermatosis indication strategy covering epidemiology, ATP2A2 biology, active trials, transactions, unmet need, competition and market…